Why the study?
Does cilazapril improve exercise tolerance and clinical status in patients with chronic heart failure stabilized on digitalis and/or diuretics?
Does cilazapril improve exercise tolerance and clinical status in patients with chronic heart failure stabilized on digitalis and/or diuretics?
In patients with chronic heart failure on standard therapy, the addition of the ACE inhibitor cilazapril significantly improves exercise tolerance and clinical symptoms.
Answers are grounded in this paper and cite their sources.
Supports cilazapril addition to digitalis/diuretics for improved exercise tolerance in chronic HF; confirms ACE inhibitor benefit on functional status.
One hundred and seven patients with chronic heart failure (NYHA class II to IV) stabilized on digitalis and/or diuretics, recruited from 11 centres were randomized into a double-blind, placebo-controlled study to assess the effect of 12 weeks of cilazapril therapy on exercise tolerance and clinical status. Thirty-five patients were randomized to placebo and 72 to cilazapril at a starting dose of 1 mg daily; titration to cilazapril 2.5 mg at week 4 and 5 mg at week 8 (or matching placebo) was carried out in patients who did not improve clinically. Demographic characteristics, including exercise test duration increased from 402 s (±17 SEM) at baseline to 462 s (±19 SEM) at week 12 for the cilazapril group (+15%) and from 405 s (±23 SEM) at baseline to 408 s (±30 SEM) at week 12 in patients on placebo (+1%) (P < 0.001). In the placebo group, patients able to exercise for more than 6 min at baseline showed an increase in exercise duration at week 12 while those able to exercise for up to 6 min at baseline showed a decrease (P = ns). In contrast, cilazapril-treated patients showed an increase in exercise tolerance regardless of baseline exercise test duration; patients with the most impaired exercise tolerance at baseline showed a greater improvement than patients with mildly impaired baseline exercise tolerance (P < 0.05 vs placebo). NYHA class improved by at least one grade in 51% of the cilazapril group vs 32% in the placebo group (P = ns). At the end of the trial, 15% of the patients were non-responders on cilazapril vs 41% on placebo (P < 0.01). A similar incidence of drop-out due to adverse events was observed in both groups (8.6% on placebo vs 8.3% on cilazapril) although adverse events were reported by fewer patients on placebo (17%) than on cilazapril (43%). Nine patients were withdrawn from the study for adverse events (three on placebo and six on cilazapril) and two patients died during the study (one in each group). Thus, in patients with chronic heart failure stabilized on digitalis and/or diuretics, angiotensin converting enzyme inhibition by cilazapril once a day was effective in prolonging exercise 'est duration, improving NYHA classification, heart failure signs and symptoms and was well-tolerated. This effect was greater in patients with the most impaired exercise tolerance at baseline.
No takes yet. Share an insight, caveat, or question.
Dössegger et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: